(Total Views: 634)
Posted On: 04/08/2020 11:29:21 PM
Post# of 153864
Most OTC companies are start ups and don't have major profit or cash flow to produce anywhere near their long term goals (should they have any- as is said in the gutter)... few have any real product to sell or staff to work it so they RS repeatedly to raise funds, diluting the security.
https://www.otcmarkets.com/learn/market-101
Very few get to any point where they can uplift even within the OTC (for example from pink to QB, and it's costly) much less to a legitimate/reputable exchange such as NYSE/Nasdaq/AMEX .
While uplisting to a better exchange could have been done once Leronlimab was FDA approved for HIV/Cancer and funds started flowing in, I believe it still would have had to do a small RS (look at VERB) in order to grow but I think now because of the unfortunate Covid-19 pandemic... bittesweet that CYDY should/could be able to uplist organically (and that's because there could be a flood of investors). CytoDyn is getting that rare opportunity to fly high... I may be off on this and it would be interesting to speak with Dr. Pourhassan about it.
Quote:
OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities.
https://www.otcmarkets.com/learn/market-101
Very few get to any point where they can uplift even within the OTC (for example from pink to QB, and it's costly) much less to a legitimate/reputable exchange such as NYSE/Nasdaq/AMEX .
While uplisting to a better exchange could have been done once Leronlimab was FDA approved for HIV/Cancer and funds started flowing in, I believe it still would have had to do a small RS (look at VERB) in order to grow but I think now because of the unfortunate Covid-19 pandemic... bittesweet that CYDY should/could be able to uplist organically (and that's because there could be a flood of investors). CytoDyn is getting that rare opportunity to fly high... I may be off on this and it would be interesting to speak with Dr. Pourhassan about it.
(0)
(0)
